Tailored approaches have been attempted to prevent HBV reinfection in HBsAg-positive liver transplant (LT) recipients in order to minimize the use of hepatitis-B-virus (HBV) specific immunoglobulins (HBIg) and nucleoside analogs (NA). We report the results of complete HBV prophylaxis withdrawal after a follow up of at least 6 years in LT recipients with undetectable serum HBV-DNA and intra-hepatic total HBV-DNA and ccc-DNA at LT
The recurrence of hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT) was...
Application of nucleoside analogues and hepatitis B immunoglobulin (HBIG) has reduced hepatitis B vi...
Background & Aims: Prophylaxis with nucleos(t)ide analogues (NUCs) and hepatitis B immunoglobulin (H...
Tailored approaches have been attempted to prevent HBV reinfection in HBsAg-positive liver transplan...
Tailored approaches have been attempted to prevent hepatitis B virus (HBV) reinfection in antibodies...
BackgroundIndefinite, long-term administration of hepatitis B immunoglobulins (HBIg), together with ...
BACKGROUND & AIMS: HBV reactivation after liver transplantation may be related to persistence of cov...
Patients after LT due to combined HBV/HDV infection are considered to be high-risk patients for recu...
Strategies using lamivudine and hepatitis B immunoglobulins (HBIg) for prevention of hepatitis B vir...
Despite universal vaccination and antiviral therapies being available for decades, chronic hepatitis...
BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis...
BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis...
Antiviral therapy using newer nucleos(t)ide analogues with lower resistance rates, such as entecavir...
WOS: 000260485500015PubMed ID: 18847315Post-transplant hepatitis B virus (HBV) recurrence prophylaxi...
The recurrence of hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT) was...
Application of nucleoside analogues and hepatitis B immunoglobulin (HBIG) has reduced hepatitis B vi...
Background & Aims: Prophylaxis with nucleos(t)ide analogues (NUCs) and hepatitis B immunoglobulin (H...
Tailored approaches have been attempted to prevent HBV reinfection in HBsAg-positive liver transplan...
Tailored approaches have been attempted to prevent hepatitis B virus (HBV) reinfection in antibodies...
BackgroundIndefinite, long-term administration of hepatitis B immunoglobulins (HBIg), together with ...
BACKGROUND & AIMS: HBV reactivation after liver transplantation may be related to persistence of cov...
Patients after LT due to combined HBV/HDV infection are considered to be high-risk patients for recu...
Strategies using lamivudine and hepatitis B immunoglobulins (HBIg) for prevention of hepatitis B vir...
Despite universal vaccination and antiviral therapies being available for decades, chronic hepatitis...
BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis...
BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis...
Antiviral therapy using newer nucleos(t)ide analogues with lower resistance rates, such as entecavir...
WOS: 000260485500015PubMed ID: 18847315Post-transplant hepatitis B virus (HBV) recurrence prophylaxi...
The recurrence of hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT) was...
Application of nucleoside analogues and hepatitis B immunoglobulin (HBIG) has reduced hepatitis B vi...
Background & Aims: Prophylaxis with nucleos(t)ide analogues (NUCs) and hepatitis B immunoglobulin (H...